Long-Term Results of Autologous Hematopoietic Cell Transplantation (Auto-HCT)-Real-Life Data of 15- and 20-Year Survivals From a Single Center.
This single-center retrospective study of 452 auto-HCT recipients treated from 1999 to 2014 reports that overall and progression-free survival continued to decline beyond 10 years, while a significant but unquantified proportion survived for 20 years.
Open original publication →What the AI sees
This single-center retrospective study of 452 auto-HCT recipients treated from 1999 to 2014 reports that overall and progression-free survival continued to decline beyond 10 years, while a significant but unquantified proportion survived for 20 years.
Research significance
The record supports long-term durability of auto-HCT for some patients with hematologic disorders; it is reasonable—but inferential—to hypothesize that disease- and risk-factor analyses could improve transplant selection and long-term surveillance, although pediatric-specific benefit is not demonstrated.
Source abstract
Over the years, autologous hematopoietic cell transplantation (auto-HCT) has become one of the most important therapeutic methods of contemporary hematology. However, analyses of survival after treatment are usually limited to 5-10 years. Data on longer survival are limited due to difficulties and loss in follow-up, as well as organizational and personnel changes in transplant centers. Therefore, our study aimed to evaluate the 15- and 20-year overall and progression-free survival of the recipients of auto-HCT in our center without exclusion of salvage indications and patients with comorbidities. During the period ranging from 1999 to 2014, there were 452 recipients of auto-HCT. Survival analyses were performed using Kaplan-Meier curves, the Cox proportional hazards model, and the log-rank test. First, the entire cohort was evaluated for 15- and 20-year overall and progression-free survival. Then, similar analyses were performed for subgroups of patients with more frequent indications, including multiple myeloma, AL amyloidosis, Hodgkin lymphoma (HL), non-Hodgkin lymphomas (NHLs), and acute myeloid leukemia. It was found that after 10 years, both overall and progression-free survival slowly but gradually declined. Still, a significant proportion of transplanted patients survived 20 years following auto-HCT, confirming the ability to cure in at least some cases of these earlier incurable disorders.